Czechia· CZ-0286311

VEVZUO

A denosumab product containing denosumab, registered in Czechia by Biosimilar Collaborations Ireland Limited, Dublin. The same ATC class is registered in 16 of our 19 countries.

ATC M05BX04

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedVEVZUOATCM05BX04REGISTER NO.CZ-0286311PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Denosumab is registered in 16 of 19 countries.

Countries holding a registration under ATC M05BX04 (denosumab), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 10 of them publish a price we can compare per daily dose

Denosumab · ATC M05BX04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of denosumab costs, country by country.

Normalised to the WHO defined daily dose (0.33 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Denosumab · price per daily dose (0.33 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

SÚKL (Czech Republic)
Active substance
DENOSUMAB
Manufacturer
Biosimilar Collaborations Ireland Limited, Dublin
Country
Czechia (CZ)
ATC code
M05BX04
ATC class
Denosumab
Defined daily dose
0.33 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0286311
    1X1,7ML
    CZK 7206.57

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

262 interactions on record for denosumab.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Denosumab · interactions on record

262 records

  • 3 severe
  • 259 moderate

Most severe, free to view

  • EtelcalcetideH05BX04severe
  • CladribineL01BB04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Denosumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All denosumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Enwylma, Ponlimsi
  • Iceland · Bildyos, Bilprevda
  • Liechtenstein · Bildyos, Bilprevda
  • Norway · Bildyos, Bilprevda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/de4c3ae3-2fa6-426f-a04d-b6ee8f7b433c
GET /v1/drugs/de4c3ae3-2fa6-426f-a04d-b6ee8f7b433c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ SOL",
  "source": "sukl",
  "strength": "120MG",
  "pack_size": "1X1,7ML",
  "substance": "DENOSUMAB",
  "cz_kod_sukl": "0286311",
  "product_type": "BT",
  "substance_codes": "17514",
  "registration_state": "R",
  "registration_number": "EU/1/25/1945/001"
}

See everything about denosumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.